AUTHOR=Yang Lei , Zeng TingTing , Li Yang , Guo Qiao , Jiang DePeng 

TITLE=Poor immune response to inactivated COVID-19 vaccine in patients with hypertension

JOURNAL=Frontiers in Medicine

VOLUME=Volume 11 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1329607

DOI=10.3389/fmed.2024.1329607

ISSN=2296-858X

ABSTRACT=Purpose: The safety and efficacy of vaccination in people with hypertension (HTN) is important. There are currently just a few data on the immunogenicity and safety of inactivated SARS-CoV-2 vaccinations in hypertension patients. Methods: After receiving a two-dose immunization, 94 hypertension adult patients and 74 healthy controls(HCs) in this study, the evaluation included looking at antibodies(Abs) against receptor binding domain (RBD) IgG, SARS-CoV-2 neutralizing antibodies(NAbs),Results: There was no discernible difference in the overall adverse events(AEs) over the course of seven or thirty days between HTN patients and HCs. HTN patients had lower frequencies of RBD-specific memory B cells and the seropositivity rates and titers of Abs compared to HCs(all, p < 0.05). HTN patients with cardiovascular and cerebrovascular conditions(CCVD) have lower titers of CoV-2 NAb than in HCs. The titers of both Abs in HTN declined gradually over time. Conclusion: Inactivated COVID-19 vaccinations were safe in hypertension patients, however humoral immune was limited, especially merge CCVD, and declined gradually over time.